| Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates |
Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago. |
zacks.com |
2025-05-08 22:40:43 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates |
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 |
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 – SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the European Association for the Study of the Liver (EASL) Congress, taking place May 7-10, 2025, in Amsterdam, the Netherlands. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? |
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-05-05 14:50:43 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress |
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – |
globenewswire.com |
2025-04-09 06:00:00 |
Czytaj oryginał (ang.) |
| Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-04-08 14:35:38 |
Czytaj oryginał (ang.) |
| Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? |
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-26 15:00:26 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights |
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – |
globenewswire.com |
2025-03-20 18:05:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus |
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes |
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – |
globenewswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B |
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – |
globenewswire.com |
2024-12-26 10:00:00 |
Czytaj oryginał (ang.) |
| Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year? |
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year. |
zacks.com |
2024-09-16 14:47:46 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop |
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – |
globenewswire.com |
2024-07-15 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 |
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 – |
globenewswire.com |
2024-06-10 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024 |
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D -- |
globenewswire.com |
2024-05-22 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights |
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights |
SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023. |
globenewswire.com |
2024-03-28 18:05:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Announces Effective Date of Reverse Stock Split |
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – |
globenewswire.com |
2024-02-08 10:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Provides Anticipated Development Milestones for 2024 |
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024. |
globenewswire.com |
2024-01-04 10:00:00 |
Czytaj oryginał (ang.) |
| 5 Penny Stocks With Big Black Friday Stock Market News |
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news, rumors, and breakthroughs – allowing traders to potentially lock in short-term gains. |
pennystocks.com |
2023-11-24 11:50:02 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023. |
globenewswire.com |
2023-11-10 18:05:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer |
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections. |
globenewswire.com |
2023-11-08 10:00:00 |
Czytaj oryginał (ang.) |
| Why Are Stocks Down Today? |
Stocks are down today and investors wondering why are in the right place as we have all the details they need to know about on Tuesday! The big reason that stocks are down today has to do with the latest retail sales report. |
investorplace.com |
2023-10-17 15:17:27 |
Czytaj oryginał (ang.) |
| Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? |
Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies have entered into a 12-year partnership agreement. |
investorplace.com |
2023-10-17 14:59:57 |
Czytaj oryginał (ang.) |
| Assembly Biosciences to Present New Data at AASLD The Liver Meeting® |
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company's interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston. |
globenewswire.com |
2023-10-11 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor |
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – |
globenewswire.com |
2023-10-02 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting |
-- Two oral presentations and one poster will feature new data from the Company's hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis B virus (HBV) and hepatitis D virus (HDV) pipeline programs at the 2023 International HBV Meeting taking place in Kobe, Japan, September 19-23, 2023. |
globenewswire.com |
2023-09-19 20:05:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop |
-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced data from development candidate ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor targeting high-recurrence genital herpes, featured in one oral and one poster presentation at the 47th Annual International Herpesvirus Workshop in Missoula, Montana, taking place July 15-19, 2023. |
None |
2023-07-17 12:00:00 |
Czytaj oryginał (ang.) |
| Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations. |
globenewswire.com |
2023-05-23 20:05:00 |
Czytaj oryginał (ang.) |
| Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board |
BOSTON--(BUSINESS WIRE)--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver. “Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic.” Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founded and brought public two biotech companies, Assembly Biosciences (NASDAQ:ASMB) and Pardes Biosciences (NASDAQ:PRDS), building both from concept through clinical development. He has helped raise over $600M for his companies to advance novel therapies for Hepatitis B (ASMB) and SARS-CoV-2 (PRDS) infections.. Dr Lopatin was also a visiting partner at Y combinator, where he focused on early stage biotech investments. Dr. Lopatin completed his training in Internal Medicine at the University of Washington, and New York University and his fellowship training in Infectious Diseases at the NIH - National Institute of Allergy and Infectious Disease. Olivia Merkel, Ph.D. Dr. Merkel has been a Professor of Drug Delivery at LMU Munich since 2015 and Chair since 2022. She is a Registered Pharmacist, received a MS (2006) and a PhD (2009) in Pharmaceutical Technology as well as numerous awards, including an ERC Starting Grant, ERC Proof-of-Concept Grant, the APV Research Award and the Carl-Wilhelm-Scheele-Award. Merkel is the author of over 100 articles and book chapters. She served as NIH reviewer from 2014-2015, SNF reviewer from 2018-2022, is an Editorial Board member for JCR, EJPB, Molecular Pharmaceutics and other journals, was the President of the German Controlled Release Society in 2020 and the Chair of the CRS Focus Group on Transdermal and Mucosal Delivery from 2020-2022. Her research focuses mainly on RNA formulation and pulmonary delivery for the treatment of a variety of lung diseases. Neville Sanjana, Ph.D. Dr. Sanjana, is a Core Faculty Member at the New York Genome Center and an Associate Professor in the Departments of Biology and of Neuroscience and Physiology at New York University. As a bioengineer, Dr. Sanjana has developed high-throughput genome engineering tools to understand the impact of genetic changes on cancer evolution, viral pathogenesis, drug resistance and the nervous system. Dr. Sanjana is a recipient of the Presidential Early Career Award for Engineers and Scientists, AAAS Wachtel Prize for Cancer Research, the NIH’s New Innovator Award, the Cancer Research Institute Technology Impact Award, the DARPA Young Faculty Award, the Kimmel Scholar Award, the MRA Young Investigator Award, and also is the Leichtung Family Investigator of the Brain and Behavior Foundation. Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University. About Carver Biosciences, Inc. Carver is a Boston, MA-based gene therapy company developing CRISPR-based therapies for RNA viruses that infect humans. Carver’s approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence. The company’s underlying technology was developed by co-founder Dr. Cameron Myhrvold. For additional information, please visit www.carver.bio. |
businesswire.com |
2023-01-17 09:00:00 |
Czytaj oryginał (ang.) |